pharmacy times logo

INTERACTIVE

HOMENEWS

Repatha® SureClick® Interactive Learning Tool for Community Pharmacists

Repatha® SureClick® Interactive Learning Tool for Community Pharmacists is sponsored by Amgen, Inc.

For this activity, you will be tasked with watching an instructional video, followed by 8 questions on how to properly prepare and use the Repatha® Single-Dose Prefilled SureClick® Autoinjector.

After answering each question, you will be prompted to view a knowledge check to confirm your answers. View Repatha® SureClick® Instructions for Use for complete description. Good luck!

Watch The Video
1

Watch the
VIDEO

2

Answer the
QUESTIONS

3

Complete the
PROGRAM

Continue

Question 1

Choose the correct labels for the parts of the Repatha® Single-Dose Prefilled SureClick® Autoinjector marked in the diagram below:

pen with labels
1
Gray start button
Window (will turn completely yellow when injection is complete)
Medicine
Expiration Date
Orange cap (on)
Yellow safety guard (needle inside)
2
Gray start button
Window (will turn completely yellow when injection is complete)
Medicine
Expiration Date
Orange cap (on)
Yellow safety guard (needle inside)
3
Gray start button
Window (will turn completely yellow when injection is complete)
Medicine
Expiration Date
Orange cap (on)
Yellow safety guard (needle inside)
4
Gray start button
Window (will turn completely yellow when injection is complete)
Medicine
Expiration Date
Orange cap (on)
Yellow safety guard (needle inside)
5
Gray start button
Window (will turn completely yellow when injection is complete)
Medicine
Expiration Date
Orange cap (on)
Yellow safety guard (needle inside)
6
Gray start button
Window (will turn completely yellow when injection is complete)
Medicine
Expiration Date
Orange cap (on)
Yellow safety guard (needle inside)
Submit Answer

Question 2

The Repatha® Single-Dose Prefilled SureClick® Autoinjector should be stored in its original carton in the refrigerator between 36°F and 46°F. True or False?

True
False
Submit Answer

Question 3

The Repatha® SureClick® Autoinjector should be allowed to reach room temperature prior to use. The patient should wait at least ____ to allow the autoinjector to warm up on its own. It is important not to heat the autoinjector by using a heat source such as hot water, direct sunlight, or the microwave. Any unused autoinjectors should be put back in the original carton and placed back in the refrigerator.

5 minutes
20 minutes
30 minutes
40 minutes
Submit Answer

Question 4

It is important to inspect the Repatha® Single-Dose Prefilled SureClick® Autoinjector prior to use. Patients should not use the autoinjector and should call
1-844-REPATHA (1-844-737-2842)
if, upon inspection, the patient notes which of the following:

It is past the expiration date printed on the label.
The autoinjector has been dropped.
The medicine is cloudy or discolored or contains particles.
The orange cap is missing or not securely attached.
Any part appears cracked or broken.
All of the above.
Submit Answer

Question 5

When the patient is ready to administer the Repatha® Single-Dose Prefilled SureClick® Autoinjector, they should first gather materials needed for the injection, wash hands thoroughly with soap and water, and place the materials on a clean, well-lit work surface. What are those materials?

The new autoinjector
An adhesive bandage
Alcohol wipes
Cotton balls or a gauze pad
Sharps disposal container
All of the above
Submit Answer

Question 6

Which of the following areas on the body are appropriate injection sites to administer the Repatha® Single-Dose Prefilled SureClick® Autoinjector?

body diagram
Upper arm (if the injection is given by someone else)
Thigh
Stomach (abdomen), except for the 2-inch area around the belly button
All of the above
Submit Answer

Question 7

Patients should only remove the orange cap from the Repatha® Single-Dose Prefilled SureClick® Autoinjector when they are ready for injection. If the orange cap is left off for more than ___ the medicine may dry out.

10 minutes
2 minutes
5 minutes
1 minute
Submit Answer

Question 8

After waiting at least 30 minutes to allow the Repatha® Single-Dose Prefilled SureClick® Autoinjector to warm up on its own, patients should then inspect the autoinjector prior to use. If the patients notice any problems with the device, such as that the date is past the expiration date printed on the label, they should call
1-844-REPATHA (1-844-737-2842).

After washing their hands thoroughly with soap and water, and gathering alcohol wipes, cotton balls or a gauze pad, an adhesive bandage, and a sharps disposal container, number the steps below in the order they should be performed.

1
2
3
4
Press the gray start button. (The patient may hear a click.) Keep pushing down for about 15 seconds. The window will turn from clear to completely yellow when the injection is done.
1
2
3
4
Wipe the injection site with an alcohol pad, allowing it to dry, and pull the orange cap off the autoinjector.
1
2
3
4
Put the yellow safety guard on the skin at a 90° angle, firmly pushing the autoinjector down onto the skin until it stops moving.
1
2
3
4
Stretch or pinch the skin in the injection site to create a firm surface by moving the thumb and fingers in opposite directions, creating an area about 2 inches wide.
Submit Answer

Congratulations!

Thank you for participating in the Repatha® SureClick® Interactive Learning Tool for Community Pharmacists

INDICATIONS

Repatha® is indicated:

  • In adults with established cardiovascular disease to reduce the risk of myocardial infarction, stroke, and coronary revascularization
  • As an adjunct to diet, alone or in combination with other low-density lipoprotein cholesterol (LDL-C)-lowering therapies, in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH) to reduce LDL-C

IMPORTANT SAFETY INFORMATION

  • Contraindication: Repatha® is contraindicated in patients with a history of a serious hypersensitivity reaction to evolocumab or any of the excipients in Repatha®. Serious hypersensitivity reactions including angioedema have occurred in patients treated with Repatha®.
  • Hypersensitivity Reactions: Hypersensitivity reactions, including angioedema, have been reported in patients treated with Repatha®. If signs or symptoms of serious hypersensitivity reactions occur, discontinue treatment with Repatha®, treat according to the standard of care, and monitor until signs and symptoms resolve.
  • Adverse Reactions in Primary Hyperlipidemia: The most common adverse reactions (>5% of patients treated with Repatha® and more frequently than placebo) were: nasopharyngitis, upper respiratory tract infection, influenza, back pain, and injection site reactions.

From a pool of the 52-week trial and seven 12-week trials: Local injection site reactions occurred in 3.2% and 3.0% of Repatha®-treated and placebo-treated patients, respectively. The most common injection site reactions were erythema, pain, and bruising. Hypersensitivity reactions occurred in 5.1% and 4.7% of Repatha®-treated and placebo-treated patients, respectively. The most common hypersensitivity reactions were rash (1.0% versus 0.5% for Repatha® and placebo, respectively), eczema (0.4% versus 0.2%), erythema (0.4% versus 0.2%), and urticaria (0.4% versus 0.1%).

  • Adverse Reactions in the Cardiovascular Outcomes Trial: The most common adverse reactions (>5% of patients treated with Repatha® and more frequently than placebo) were: diabetes mellitus (8.8% Repatha®, 8.2% placebo), nasopharyngitis (7.8% Repatha®, 7.4% placebo), and upper respiratory tract infection (5.1% Repatha®, 4.8% placebo).

Among the 16,676 patients without diabetes mellitus at baseline, the incidence of new-onset diabetes mellitus during the trial was 8.1% in patients treated with Repatha® compared with 7.7% in patients that received placebo.

  • Immunogenicity: Repatha® is a human monoclonal antibody. As with all therapeutic proteins, there is potential for immunogenicity with Repatha®.

Please see full Prescribing Information.

© 2021 Amgen Inc. All rights reserved. USA-145-82951 04/21

Copyright Pharmacy Times 2006-2020

Pharmacy & Healthcare Communications, LLC. All Rights Reserved.